https://www.selleckchem.com/products/ag-270.html
After a median follow-up of 41 months (8 to 74 mo), all patients (100%) are alive, healthy, with complete clinical, immunologic, and hematologic recovery, without signs of WAS. This limited study with high-dose PBSC transplantation approach for WAS, demonstrated a safe and effective treatment option, with rapid engraftment, without complications, excellent long-term outcomes, independent of conditioning regimen. This limited study with high-dose PBSC transplantation approach for WAS, demonstrated a safe and effective treatment option, wi
Like
Comment
Share
